Get startedLog in
    Picture of Dawnrays Pharmaceutical (Holdings) logo

    2348 — Dawnrays Pharmaceutical (Holdings) Income Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareBalancedSmall CapSuper Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Dawnrays Pharmaceutical (Holdings), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    HKAS
    HKAS
    HKAS
    HKAS
    HKAS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue1,0241,1651,2781,1511,060
    Cost of Revenue
    Gross Profit551675767628532
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses669679777695416
    Operating Profit355486501456644
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes331439438414637
    Provision for Income Taxes
    Net Income After Taxes265354356323563
    Minority Interest
    Net Income Before Extraordinary Items
    Net Income268358358326565
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income268358358326565
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS0.1750.2010.2170.2170.209
    Dividends per Share
    Special Dividends per Share